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Abstract
Background: More knowledge about genetic and molecular features of cholangiocarcinoma is needed to develop
effective therapeutic strategies. We investigated the clinical and pathological significance of ROS1 expression in
intrahepatic cholangiocarcinoma.
Methods: One hundred ninety-four patients with curatively resected intrahepatic cholangiocarcinoma were
included in this study. Tumor tissue specimens were collected and analyzed for ROS1 gene rearrangement using
fluorescence in situ hybridization (FISH) and ROS1 protein expression using immunohistochemistry (IHC).
Results: ROS1 immunohistochemistry was positive (moderate or strong staining) in 72 tumors (37.1 %). ROS1
protein expression was significantly correlated with well differentiated tumors, papillary or mucinous histology,
oncocytic/hepatoid or intestinal type tumors, and periductal infiltrating or intraductal growing tumors (vs. mass-
forming cholangiocarcinoma). ROS-expressing tumors were associated with better disease-free survival (30.1 months
for ROS1 expression (+) tumors vs. 9.0 months for ROS1 (−) tumors, p = 0.006). Moreover, ROS1 expression was an
independent predictor of better disease-free survival in a multivariate analysis (HR 0.607, 95 % CI 0.377–0.976;
p = 0.039). Although break-apart FISH was successfully performed in 102 samples, a split pattern indicative of ROS1
gene rearrangement was not found in the examined samples.
Conclusion: ROS1 protein expression was associated with well-differentiated histology and better survival in our
patients with resected intrahepatic cholangiocarcinoma. ROS1 gene rearrangement by break-apart FISH was not
found in the examined samples.
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Background
Biliary tract cancer (BTC) is an aggressive disease with a
very poor prognosis with a median survival of less than
1 year [1]. It is a heterogeneous group of disease includ-
ing intrahepatic, perihilar, or distal cholangiocarcinoma
and gallbladder cancer, with diverse epidemiology, eti-
ology, and pathogenesis. Among them, intrahepatic chol-
angiocarcinoma is a distinct disease with increasing
incidence in the western countries and worldwide, and
its etiology and molecular pathogenesis differs from the
other BTCs [2]. Five-year survival rate after curative sur-
gery for intrahepatic cholangiocarcinoma remains poor
ranging 20–32 %, and this is poorer than that for hilar
cholangiocarcinoma (30–42 %), and for distal cholangio-
carcinoma (18–54 %) [3–5]. Understanding its molecular
features and developing new effective strategies are ur-
gent and important; however, the molecular and genetic
features of BTCs have been inadequately investigated in
comparison to other common solid malignancies.
ROS1 is a receptor tyrosine kinase (RTK) oncogene
that activates the SH2 domain tyrosine phosphatases
SHP-1 and SHP-2, the mitogen-activated protein kinase
ERK1/2, insulin receptor substrate 1 (IRS-1), phos-
phatidylinositol 3-kinase (PI3K), protein kinase B (AKT),
STAT3 and VAV3 signaling pathways [6]. The expres-
sion of ROS1 was found in human cancers of the central
nervous system, stomach, liver, kidney, and colon [6].
Moreover, gene rearrangement of ROS1 has been found
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in nonsmall cell lung cancer (NSCLC) [7–11], glioblast-
oma multiforme [12], gastric cancer [13], and colon can-
cer [14]. These rearrangements create fusion proteins in
which the kinase domain of ROS1 becomes constitu-
tively active and drives cellular proliferation. Crizotinib,
an oral MET/anaplastic lymphoma kinase (ALK) inhibi-
tor, has shown encouraging clinical activity in ROS1-
rearranged NSCLC, indicating that ROS1 rearrangement
is a driver mutation in NSCLC [8, 15, 16]. Thus, the ac-
tivity of crizotinib is of significant interest for the treat-
ment of ROS1-rearranged tumors.
Recently, Gu et al. found a fusion of the ROS1 gene
with the FIG gene in 2 out of 23 patients (8.7 %) with
cholangiocarcinoma; the authors suggested that this
could be a driver mutation, because it confers trans-
forming activity to bile duct cells and can be effectively
blocked with an ROS1 tyrosine kinase inhibitor [17]. In-
deed, cholangiocarcinoma with ROS1 gene fusion would
be a good candidate for treatments targeting ROS1 such
as crizotinib; however, the actual incidence and clinical
significance of ROS1 rearrangements in BTC have not
been fully known.
We aimed to investigate both protein expression and
gene fusion of ROS1 in a larger number of patients with
intrahepatic cholangiocarcinoma. Immunohistochemistry
and fluorescence in situ hybridization (FISH) analysis
were performed and correlated with clinicopathologic
features.
Methods
Patients and clinicopathologic parameters
Patients who underwent curative surgery for intrahepatic
cholangiocarcinoma at Seoul National University Hos-
pital, Seoul, Republic of Korea, from 1992 to 2010, and
had available medical records and formalin-fixed paraffin
blocks of tumor were eligible for analysis. Clinical infor-
mation including age, sex, size of tumor, and surgical
methods was collected from the medical records; patho-
logic information including differentiation, histologic
type, gross type, vascular invasion, and perineural inva-
sion was collected form pathology reports and slide re-
view. Criteria for pT (pathologic T stage) followed the
intrahepatic bile duct tumor staging of American Joint
Committee on Cancer 7th edition [18] Tumor differenti-
ation was categorized based on the grading system de-
scribed by the World Health Organization classification
[19]. Adjuvant chemotherapy and/or radiotherapy were
at the physician’s discretion considering histology and
lymph node involvement. This study was carried out in
compliance with the Helsinki Declaration and approved
by the Institutional Review Board of Seoul National
University Hospital (H-1011-046-339). Informed con-
sent was waived by the Institutional Review Board of
Seoul National University Hospital.
Construction of tissue microarray and
immunohistochemical staining
Suitable areas with two representative tumor areas for
each case were marked on the H&E stained sections,
then core tissue specimens (2 mm in diameter) were col-
lected from individual paraffin-embedded tissues and
rearranged in new tissue array blocks by using a trephine
apparatus (SuperBioChips Laboratories, Seoul, Korea).
Each tissue microarray had four cores of normal liver,
normal bile duct, and normal gastrointestinal tract mu-
cosa as internal controls. Sections (4 μm) were stained
for ROS1 (ROS1(D4D6) rabbit monoclonal antibody, cat.
number #3287 1:10 dilution, Cell Signaling Technology,
Beverly, MA) after an antigen retrieval process using Bond
Epitope Retrieval Solution 2 at 99 °C for two minutes
(Leica Biosystems, Wetzlar, Germany). The slides were
automatically stained using Bond-Max IHC and ISH slide
stainer and a Bond Polymer Refine Detection Kit (Leica
Biosystems, Wetzlar, Germany).
Evaluation of immunohistochemistry
Positive staining for ROS1 was observed in cytoplasm;
the intensity of staining was graded as negative; no stain-
ing in any cellular component, weak (1+); faint staining
in cytoplasm, moderate (2+); unequivocal positive stain-
ing with negative background staining, or strong (3+);
strong cytoplasmic staining with negative background
staining. Because stained pattern was not patched but
usually diffuse, we could not separately evaluate the area
of positive cells, but 5 % of tumor cells was used as a
cutoff value for positive staining. For comparative ana-
lysis of protein expression and clinicopathologic parame-
ters, dichotomized values such as positive and negative
were used and the criteria of positivity was ≥2+ intensity
in ≥5 % of tumor cells.
ROS1 break-apart fluorescence in situ hybridization
(FISH) assay
Break-apart FISH probe consisted of the distal part of
Exon 30 of ROS1(6q22) (RH104060-SHGC-14420)) dir-
ectly labeled with PlantinumBrightTM550 (red signal)
and the proximal part of Exon 42 of ROS1(6q22)
(RH69070-RH68126) directly labeled with Platinum-
BrightTM495 (green signal) (Repeat-FreeTM PseidonTM
ROS1 (6q22) Break probe, KBI-10752, Kreatech Diag-
nostics, Amsterdam, Netherlands). Briefly, 2 micrometer
sections were deparaffinized and dehydrated. The slides
were treated with pretreatment reagent (Abott Molecu-
lar, Des Plaines, IL) at 80 °C for 40 min and reacted with
protease powder (Abott Molecular, Des Plaines, IL) in
protease buffer at room temperature after HCL and
microwave treatment. The probe set was applied and in-
cubated in ThermoBrite (Abbott Molecular, Des Plaines,
IL) at 80 °C for 10 min to denature the probes followed
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by incubation at 37 °C for 16 h to allow hybridization.
The samples were analyzed using an X100 oil immersion
lens on an Olympus BX-51TRE microscope (Olympus,
Tokyo, Japan) equipped with DAPI, green, orange, aqua,
and triple-pass (DAPI/Green/Orange) filters (Abbott-
Vysis). At least 50 nuclei per sample were assessed. Sig-
nals were evaluated as: (a) no gene rearrangement on
either chromosome, i.e. two sets of separate red and
green signals, (b) gene rearrangement on one chromo-
some, i.e. one combined signal and one separate red and
green signal, and (c) deletion of the distal portion of
ROS1 as indicated by one combined signal and a single
green signal found in >15 % of tumor cells [9]. Specimen
from non-small cell lung cancer with ROS1 fusion was
used as a positive control.
Statistical analysis
Comparative analysis of clinicopathologic parameters
was evaluated using the chi-squared (χ2) test or Fisher’s
exact test. Survival analysis was performed using Kaplan-
Meier analysis and Cox’s proportional hazard model.
Disease-free survival (DFS) was defined as the time from
the surgery until the patient survives without any signs or
symptoms of the cancer. Overall survival (OS) was defined
as the time to any cause of death. The results were
considered statistically significant when p values were <
0.05. All tests were performed using IBM SPSS version 21.
Results
Patient demographics
The number of patients who received liver resection for
intrahepatic cholangiocarcinoma was 309, and excluding
those whose surgery was not curative or R0 resection
and those whose tumor tissue or clinical data were not
available, 194 patients were finally included in the
current study (Fig. 1). The demographic characteristics
of the patients are summarized in Table 1. Briefly, 149
(76.8 %) of patients were male, and the median age of
the entire population was 62 years. With regard to the
known underlying liver disease and etiology of cholan-
giocarcinoma, 15 patients had chronic hepatitis, 12 of
whom had hepatitis B virus infection and 3 had hepatitis
C virus infection; three patients had infection of clo-
norchis sinensis; and 3 patients had hepatolithiasis.
Most patients received lobectomy or hemihepatectomy
of the liver (n = 129, 66.5 %), followed by segmentectomy
(n = 54, 28.1 %) and others (n = 11, 5.7 %). Tumor size
ranged from 0.3 to 26.0 cm (mean tumor size 5 cm), and
19 patients (10.1 %) had more than 1 tumor in the liver.
Lymph node involvement by the tumors was found in 45
Fig. 1 Selection of patients. This diagram summarized the selection of patients included in the study. Out of 555 patients who received liver
resection for cholangiocarcinoma, 194 patients with curatively resected intrahepatic cholangiocarcinoma were included in the analysis
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Table 1 ROS1 expression and clinicopathologic parameters
ROS1 expression N (%) Negative Positive p.
122 (62.9) 72 (37.1)
Sex (194) Male 149 (76.8) 96 (64.4) 53 (35.6) 0.418
Female 45 (23.2) 26 (57.8) 19 (42.2)
Age (yr) (194) 62 [37–89] 60.1 ± 9.0 61.5 ± 10.4 0.347
Size (cm) (185) 5.0 [0.3–26.0] 5.5 ± 2.9 5.6 ± 3.9 0.673
Operation (183) Lobectomy 129 (70.5) 84 (65.1) 45 (34.9) 0.635
Segmentectomy 54 (29.5) 32 (59.3) 22 (40.7)
Number (188) Single 169 (89.9) 107 (63.3) 62 (36.7) 0.114
Multiple 19 (10.1) 14 (73.7) 5 (26.3)
Gross type (189) Mass forming 133 (70.4) 91 (68.4) 42 (31.6) 0.006*
Periductal infiltrating 10 (5.3) 5 (50.0) 5 (50.0)
Intraductal polypoid 24 (12.7) 8 (33.3) 16 (66.7)
Mixed 22 (11.6) 16 (72.7) 6 (27.3)
Extent of tumor (188) Confined liver 92 (48.9) 50 (54.3) 42 (45.7) 0.005*
Extrahepatic invasion 96 (51.1) 71 (74.0) 25 (26.0)
pT stage (190) Tis 1 (0.5) 1 (100) 0 (0.0) 0.226
T1 86 (45.3) 52 (60.5) 34 (39.5)
T2a 39 (20.5) 21 (53.8) 18 (46.2)
T2b 12 (6.3) 9 (75.0) 3 (25.0)
T3 50 (26.3) 37 (74.0) 13 (26.0)
T4 2 (1.1) 1 (50.0) 1 (50.0)
pN stage (106) pN0 61 (57.5) 35 (57.4) 26 (42.6) 0.462
pN1 45 (42.5) 29 (64.4) 16 (35.6)
Resection margin (177) R0 151 (85.3) 100 (66.2) 51 (33.8) 0.400
R1-2 26 (14.7) 15 (57.7) 11 (42.3)
Lymphatic invasion (187) Absent 117 (62.6) 71 (60.7) 46 (39.3) 0.278
Present 70 (37.4) 48 (68.6) 22 (31.4)
Vascular invasion (180) Absent 127 (70.6) 81 (63.8) 46 (36.2) 0.595
Present 53 (29.4) 36 (67.9) 17 (32.1)
Neural invasion (184) Absent 137 (74.5) 89 (65.0) 48 (35.0) 0.687
Present 47 (25.5) 29 (61.7) 18 (38.3)
Differentiation (194) Well 34 (17.5) 14 (41.2) 20 (58.8) 0.150
Moderate 112 (57.7) 75 (67.0) 37 (33.0)
Poor 48 (24.7) 33 (68.8) 15 (31.3)
Histologic subtype (194) Adenocarcinoma, tubular 167 (86.1) 111 (66.5) 56 (33.5) 0.009*
Papillary or mucinous carcinoma 15 (7.7) 4 (26.7) 11 (73.3)
Othersa 12 (6.2) 7 (58.3) 5 (41.7)
Cell type (172) Nonintestinal type 137 (79.7) 92 (67.2) 45 (32.8) 0.019*
Intestinal type 35 (20.3) 19 (54.3) 19 (54.3)
Progression (194) No evidence of disease 62 (32.0) 34 (54.8) 28 (45.2) 0.024*
Recurrence or metastasis 119 (61.3) 83 (69.7) 36 (30.3)
Censored 13 (6.7) 5 (38.5) 8 (61.5)
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patients among 106 patients whose lymph nodes were
resected and assessed. Histological subtypes of resected
tumors included adenocarcinoma in 167 (86.1 %), papil-
lary or mucinous carcinoma in 15 (7.7 %), and others in
12 (6.2 %). Tumors were classified as well-differentiated in
34 (17.5 %), moderately-differentiated in 112 (57.7 %), and
poorly-differentiated in 48 (24.7 %). Adjuvant treatment
was given to 25 patients (12.9 %), of whom 13 chemother-
apy, 1 radiotherapy, and 11 concurrent chemoradiation.
After median follow-up period of 30.0 months (range
1–196) after surgery, 119 (61.3 %) patients had recurrent
disease, and 62 patients remained disease-free. One hun-
dred twenty-six (64.9 %) patients had deceased at the
time of analysis.
Immunohistochemical analysis and break-apart
fluorescence in situ hybridization of ROS1
Representative expression patterns of ROS1 are pre-
sented in Fig. 2. Positive ROS1 staining was observed in
the cytoplasm in a diffuse pattern. In 70 samples
(36.1 %) staining was moderate, while in two samples
(1.0 %) staining was strongly positive; in 62 samples
(32.0 %) showed weak intensity and remaining 60 cases
(30.9 %) were negatively stained (Table 2). FISH was per-
formed in 194 samples, and its signal was detected in
102 samples, but evidence of gene rearrangement (split
pattern using break-apart FISH) was not found in the
examined samples.
Correlation of ROS1 expression and clinicopathological
features of the patients
Clinicopathologic features listed according to ROS1 ex-
pression level are summarized in Table 1. The group
with positive staining included 72 moderate to strongly
stained samples (37.1 %).
ROS1-expressing tumors were more frequent in peri-
ductal (50.0 %) or intraductal type (66.7 %) than mass
forming type (31.6 %) as characterized according to the
Table 1 ROS1 expression and clinicopathologic parameters (Continued)
Death (194) Alive 60 (30.9) 32 (53.3) 28 (46.7) 0.176
Deceased 126 (64.9) 85 (67.5) 41 (32.5)
Censored 8 (4.1) 5 (62.5) 3 (37.5)
Median [range]; mean ± sd
*p < 0.05
aUndifferentiated carcinoma, adenosquamous carcinoma, mixed adenocarcinoma and neuroendocrine carcinoma
Fig. 2 Immunohistochemical staining for ROS1. Tumor sections were stained for ROS1 with rabbit monoclonal antibody (D4D6), purchased from
Cell Signaling Technology, Beverly, MA. The intensity of cytoplasmic staining was graded as (a) strong (3+); strong cytoplasmic staining with
negative background staining, (b) moderate (2+); unequivocal positive staining with negative background staining, (c) weak (1+); faint staining in
cytoplasm, or (d) negative; no staining in any cellular component. The photographs were taken at a magnification of x200
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histologic subtypes proposed by the Liver Cancer Study
Group of Japan [20, 21]. Microscopic features of tu-
mors with ROS1 expression were significantly related
to well differentiated histology, papillary or mucinous
tumors, and intestinal type. In addition, the stage at the
time of surgery was lower in ROS1-expressing tumors,
with a higher proportion of T1 or T2 stage tumors as
compared to later stage tumors and less invasion into
adjacent organs. The expression of ROS1 did not sig-
nificantly correlate with known risk factors or etiologies
of cholangiocarcinoma, or the adjuvant treatments.
Univariate and multivariate survival analysis of ROS1
expression
ROS1-expressing tumors were associated with better
disease-free survival (Fig. 3). Median disease-free survival
for ROS1-expressing (+) tumors and non-expressing (−)
tumors was 30.1 months and 9.0 months, respectively
(p = 0.006). Median overall survival was 43.0 months
and 21.7 months, respectively (p = 0.071).
As extensive lymph node dissection is not routinely
performed during curative surgery of intrahepatic chol-
angiocarcinoma, we confined the multivariate survival
analysis to the patients without lymph node metastasis.
With covariates including tumor size, gross appearance,
multiplicity of tumors, tumor histology, differentiation,
and the presence of vascular, neural, or lymphatic inva-
sion, ROS1 expression was an independent predictor of
longer disease-free survival (HR 0.607, 95 % CI 0.377–
0.976; p = 0.039, Table 3).
Discussion
Molecular pathogenesis of intrahepatic cholangiocarci-
noma is of particular importance, not only because it is
fatal disease with increasing incidence, but also little has
been known compared to other common cancers [2].
EGF, HGF/MET, VEGF, KRAS/MAPK, and IL-6/STAT
pathways have been found to be deregulated in cholan-
giocarcinoma, but no effective therapies targeting these
pathways have been developed. There is an eager need
for more knowledge and clinical application in the field
of this disease. As rearrangement of ROS1 gene was re-
ported in cholangiocarcinoma recently [17, 22], and ROS1
inhibitors such as crizotinib or foretinib (GSK1363089)
have shown remarkable activity in ROS1-driven tumors
[8, 16, 23], the actual incidence of protein expression and
gene rearrangements of ROS1, as well as its clinical sig-
nificance in BTC, were pursued in the present study.
ROS1 was discovered more than 30 years ago as an
oncogene, but it is one of the last few remaining orphan
Table 2 The positivity of ROS1 by immunohistochemistry
ROS1 staining Number Percent Number Percent
0 60 30.9 % Negative 122 62.9 %
1+ 62 32.0 %
2+ 70 36.1 % Positive 72 37.1 %
3+ 2 1.0 %
Total 194 100 % Total 194 100 %
Fig. 3 Kaplan-Meier curves for disease-free survival and overall survival according to ROS1 expression. ROS-expressing tumors were associated
with better disease-free survival (30.1 months for ROS1 expression (+) tumors vs. 9.0 months for ROS1 (−) tumors, p = 0.006). Also, patients with
ROS1 (+) tumors had better overall survival, not reaching statistical significance (p = 0.071)
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receptor tyrosine kinases with an as yet unidentified lig-
and, and its normal functions have not been fully identi-
fied so far [24]. It is expressed in human cancers such as
glioblastoma, and cancers of stomach, liver, kidney and
colon [6]. Wild-type ROS1 has been shown to have
transformative activity with downstream signaling of the
SH2 domain tyrosine phosphatases SHP-1 and SHP-2,
the mitogen-activated protein kinase ERK1/2, insulin re-
ceptor substrate 1 (IRS-1), phosphatidylinositol 3-kinase
(PI3K), protein kinase B (AKT), STAT3 and VAV3 sig-
naling pathways [6]. Importantly, fusion proteins created
by the rearrangements also have the kinase domain of
ROS1 and it becomes constitutively active and drives
cellular proliferation. Both wild-type and rearranged
ROS1 have transformative activity attributable to its kin-
ase domain.
Fusion of ROS1 gene was first found in 2 out of 23
BTCs (8.7 %) [17], but there have been scarce reports
following the original study. Recently, ROS1 alterations
were found in 1 out of 100 (1 %) patients with intrahe-
patic cholangiocarcioma [25]. In another report, ROS1
fusion was found in 14–16 % of patients with gallbladder
carcinoma or extrahepatic cholangiocarcinoma, but not
those with intrahepatic cholangiocarcinoma [26]. We
could not find any ROS1 rearrangement by FISH in 102
Korean patients with intrahepatic cholangiocarcinoma.
The actual incidence of ROS1 rearrangement in intrahe-
patic cholangiocarcinoma is expected to be lower than
that previously reported due to ethnic and environmen-
tal differences [27].
Although ROS1 gene rearrangements were not found,
ROS1 protein expression was found in significant por-
tion of BTCs. Interestingly, it was related to specific
characteristics of tumors and better disease-free survival.
ROS1 expression was more common in well-differentiated
tumors than in moderately- or poorly-differentiated tu-
mors. Specifically, papillary or mucinous carcinomas were
strongly related to expression of the ROS1 protein
(73.3 %). The gross appearance of cholangiocarcinoma is
divided into three types: mass-forming, periductal infil-
trating, intraductal growth type [20, 21]. The mass-
forming subtype is the most common and spreads via
venous and lymphatic vessels, exhibiting poorer prognosis
[28, 29]. ROS1-expressing tumors were periductal or
intraductal (50 % and 33.3 %, respectively) rather than
mass forming (31.6 %). In general, ROS1 expression is re-
lated to less aggressive tumors, well differentiated features,
and better survival in BTC.
ROS1 expression was also a predictor of favorable sur-
vival in NSCLC, as well as BTC. In a large cohort of
1478 NSCLCs, ROS1 expression was correlated with
better survival and specific features such as low T stages,
TTF1 and napsin expression, and certain histomorpho-
logical adenocarcinoma patterns (lepidic, acinar, and
solid) [30], although there is also a contradictory data
[31]. Moreover, gastric adenocarcinomas expressing
ROS1 by immunohistochemistry tended to present with
differentiated tumors and lower lymph node status [13].
Similar results were found in breast cancer with regard
to histologic grade, mitotic count, estrogen receptor ex-
pression, and Ki-67 proliferation index [32]. The patho-
genic role of ROS1 is suggested in these specific tumor
types as in BTCs.
ROS1 expression as determined by IHC was moderate
to strong in 38 % of tumors, but gene rearrangement
assessed by FISH was not found in our patients. This is
in contrast to the previous reports in NSCLC, where
IHC and FISH results were strongly correlated. The sen-
sitivity and specificity of ROS1 IHC for rearrangements
by FISH is reported to be more than 90 % [33–35] and,
as such, IHC is suggested as an effective screening tool
in NSCLC. The threshold level for ROS1 positive ex-
pression in IHC differs among reports, but 2+ or moder-
ate expression is usually considered to be positive. In
Table 3 Disease free survival and ROS1 expression
Univariate Multivariate
Median(m) p. HR [95 % CI] p.
ROS1 expression Negative vs. positive 9 vs. 30 0.006 0.58 [0.37–0.89] 0.014
Size of tumor Cm 1.053a 0.008 1.06 [1.01–1.11] 0.019
Number of tumor Single vs. multiple 15 vs. 4 0.001 2.27 [1.24–4.16] 0.008
Gross type Mass forming vs. periductal 9 vs. 89 <0.001 0.48 [0.24–0.98] 0.042
Differentiation Well vs. moderate to poor 89 vs. 9 <0.001 2.22 [1.09–4.51] 0.028
Perineural invasion Absent vs. present 19 vs. 9 0.039 1.63 [1.04–2.55] 0.034
Vascular invasion Absent vs present 15 vs. 8 0.051
Lymphatic invasion Absent vs present 19 vs. 8 0.009
Histologic type Papillary/mucinous vs. NA vs. 11 0.026
Tubular/undifferentiated
aMean hazard ratio by Cox proportional hazard model; HR, hazard ratio; CI, confidential interval
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contrast, a significant portion of cholangiocarcinoma
samples exhibited greater than moderate expression of
ROS1, yet we could not find any ROS1 gene rearrange-
ment by FISH. Therefore, we conclude that ROS1 IHC
cannot be used as a screening tool for ROS1 rearrange-
ment in BTC.
As protein expression of ROS1 does not directly indi-
cate fusion and activation of the ROS1 gene in BTCs, we
should be cautious in selecting treatment strategies for
these tumors. As the expression of ROS1 was related
not only to gene rearrangements, but also to other bio-
logical processes as epigenetic changes [31], further re-
search on biological and clinical role of ROS1 expression
is warranted. Inhibition of both ROS1 and its frequent
fusion partner FIG in the HuCCT1 cell line, which ex-
presses ROS1 protein, led to decreased cell proliferation,
although the existence of FIG-ROS1 fusion protein was
not specified in the article [36]. More data regarding
biological and clinical role of ROS1 expression, as well
as the effects of specific inhibitors of ROS1 in BTCs are
needed.
Conclusion
ROS1 protein expression was associated with well-
differentiated histology and better survival in patients
with resected intrahepatic cholangiocarcinoma. ROS1
gene rearrangement by break-apart FISH was not found
in the examined samples.
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